Investigating FDA-approved drugs in an animal model of KCNT1-childhood epilepsy to identify potential new therapies for treating children

Chief Investigator: Professor Leanne Dibbens Funding Amount: $ 100,000 Recipient: University of South Australia Overview: KCNT1 mutations cause one of the most severe forms of epilepsy in children, resulting in